Life Seal Vascular lands $1.25M NSF grant to push aortic device toward FDA trials
What's the deal? Life Seal Vascular (LSV)Dealroom has a profile for this one. Try Dealroom →, an Irvine-based medical technology company, has been awarded a $1.25 million Phase II Small Business Innovation Research (SBIR) grant from the US National Science FoundationDealroom has a profile for this one. Try Dealroom →. The non-dilutive funding will advance its Cygnum Aneurysm Sac Management Device toward an FDA clinical trial submission.
What's the endgame? LSV develops sealing technologies for endovascular aortic repair. Its Cygnum device works as an adjunct to conventional endografts, targeting endoleaks — a primary failure point in endovascular abdominal aortic aneurysm repair (EVAR). The company aims to establish a new product category in the vascular device industry.
Where the money goes: The grant funds preclinical development and pre-Investigational Device Exemption (pre-IDE) work, accelerating LSV's path to an FDA IDE clinical trial submission and approval. The Cygnum device recently completed a first-in-human trial.
Why now? The award follows those trial results and lets LSV fund its R&D pipeline without diluting existing shareholders ahead of commercialisation milestones. "This competitive, non-dilutive support allows us to build meaningful company value," said Matt Thompson, co-chief executive officer.
By the numbers: The grant sits in roughly the 34th percentile by size — smaller than most funding rounds tracked, reflecting the early, milestone-based nature of federal SBIR support. NSF's America's Seed FundDealroom has a profile for this one. Try Dealroom → awards $200 million annually and can provide startups up to $2 million.
The signal: Non-dilutive federal grants remain a key funding path for early-stage medtech, letting companies de-risk technology before raising equity. For LSV, the award serves as government validation of both the science and commercial potential ahead of costly clinical trials.
Read more: einpresswire.com
Image credit: Generated with Gemini
